DENTSPLY SIRONA Inc.

NasdaqGS:XRAY Stock Report

Market Cap: US$6.3b

DENTSPLY SIRONA Past Earnings Performance

Past criteria checks 0/6

DENTSPLY SIRONA's earnings have been declining at an average annual rate of -10.4%, while the Medical Equipment industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 0.9% per year.

Key information

-10.4%

Earnings growth rate

-11.5%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate0.9%
Return on equity-4.0%
Net Margin-3.3%
Next Earnings Update02 May 2024

Recent past performance updates

Recent updates

Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader

Apr 24

Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?

Apr 22
Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?

There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues

Mar 10
There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues

Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden

Feb 16
Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden

DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward

Jan 29
DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate

Jan 11
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate

Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?

Nov 25
Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?

These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively

Nov 06
These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively

Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture

Oct 15
Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture

An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued

Sep 18
An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued

DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet

Jul 31
DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet

The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing

Jul 09
The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing

A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Jun 20
A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?

Jun 02
When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?

Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel

May 15
Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel

The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing

Apr 05
The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing

Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?

Mar 07
Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?

We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt

Nov 09
We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt

Dentsply Sirona names Glenn Coleman as new CFO

Sep 22

Dentsply Sirona hires Simon Campion as president, CEO

Aug 25

Dentsply Sirona receives noncompliance notice from Nasdaq

Aug 16

Dentsply Sirona: Weakening Fundamentals Outweigh 'Defensives' Argument

Jul 18

Dentsply Sirona Seems Unaffected By Management Reshuffles

May 02

Investors Will Want DENTSPLY SIRONA's (NASDAQ:XRAY) Growth In ROCE To Persist

Apr 29
Investors Will Want DENTSPLY SIRONA's (NASDAQ:XRAY) Growth In ROCE To Persist

DENTSPLY SIRONA (NASDAQ:XRAY) Seems To Use Debt Rather Sparingly

Mar 16
DENTSPLY SIRONA (NASDAQ:XRAY) Seems To Use Debt Rather Sparingly

Revenue & Expenses Breakdown
Beta

How DENTSPLY SIRONA makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:XRAY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 233,965-1321,617184
30 Sep 233,936-2141,611184
30 Jun 233,936-1,0251,640179
31 Mar 233,931-1,0381,635175
31 Dec 223,922-9501,596174
30 Sep 224,042-8161,564180
30 Jun 224,1353451,552178
31 Mar 224,1743681,536176
31 Dec 214,2314111,547171
30 Sep 214,2074011,535166
30 Jun 214,0623701,458154
31 Mar 213,4911791,323129
31 Dec 203,339-731,309123
30 Sep 203,371-801,275210
30 Jun 203,438-481,340183
31 Mar 203,957841,510165
31 Dec 194,0222561,578143
30 Sep 193,9771621,520161
30 Jun 193,9441051,560161
31 Mar 193,976-1,0531,562161
31 Dec 183,986-1,0111,551161
30 Sep 184,018-1,6631,560152
30 Jun 184,098-1,6011,578152
31 Mar 184,049-1,5291,563152
31 Dec 173,993-1,5501,532152
30 Sep 173,899-7931,501129
30 Jun 173,844-7911,443129
31 Mar 173,8733651,427129
31 Dec 163,7454301,374129
30 Sep 163,4203821,30775
30 Jun 163,1153741,19275
31 Mar 162,7913121,06575
31 Dec 152,67425199375
30 Sep 152,7222771,01181
30 Jun 152,7822681,01781
31 Mar 152,8493141,03881
31 Dec 142,9233231,06281
30 Sep 142,9573131,06185
30 Jun 142,9533171,06085
31 Mar 142,9493141,05485
31 Dec 132,9513131,06085
30 Sep 132,9503661,05585
30 Jun 132,9423391,04685

Quality Earnings: XRAY is currently unprofitable.

Growing Profit Margin: XRAY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: XRAY is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.

Accelerating Growth: Unable to compare XRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XRAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).


Return on Equity

High ROE: XRAY has a negative Return on Equity (-4.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.